Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742721 | 0.82 | TDP1 (0.70) | TDP1PKMPTGDR2MAPTTSHR | |
| SCHEMBL1369720 | 0.82 | PTGDR2 (0.64) | TDP1PKMPTGDR2TSHRPOLB | |
| SCHEMBL1332580 | 0.82 | TDP1 (0.70) | TDP1PTGDR2MAPTTSHR | |
| SCHEMBL3046012 | 0.82 | PTGDR2 (0.54) | TDP1PKMPTGDR2MAPTTSHR | |
| SCHEMBL1028925 | 0.82 | PTGDR2 (0.60) | TDP1PKMPTGDR2MAPTTSHR | |
| SCHEMBL9905095 | 0.82 | PKM (0.50) | TDP1PKMPTGDR2MAPTTSHR | |
| SCHEMBL10228587 | 0.80 | PTGDR2 (0.51) | TDP1PKMPTGDR2MAPTTSHR | |
| SCHEMBL4977225 | 0.80 | PTGDR2 (0.54) | TDP1PKMPTGDR2MAPTTSHR | |
| SCHEMBL4684755 | 0.79 | TDP1 (0.56) | TDP1PTGDR2MAPTTSHRPOLB | |
| SCHEMBL5280821 | 0.78 | PTGDR2 (0.63) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED (US) | 2015-02-05 | — | — | US | claimed |
| WO-2012162697-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-11-29 | — | — | WO | claimed |
| US-7015247-B2 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN | 2006-03-21 | — | — | US | claimed |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN (US) | 2003-01-09 | — | — | US | claimed |
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | GUTTAG ALVIN (US) | 2002-05-30 | — | — | US | claimed |
| US-9629848-B2 | Compounds that modulate autoimmunity and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-04-25 | — | — | US | disclosed |
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED (US) | 2015-02-05 | — | — | US | disclosed |
| WO-2012162697-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-11-29 | — | — | WO | disclosed |
| US-7015247-B2 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN | 2006-03-21 | — | — | US | disclosed |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN (US) | 2003-01-09 | — | — | US | disclosed |
| US-6436916-B1 | PHENOLIC ESTERS OF IBUPROFEN WITH SALICYLIC ACID OR ITS NONTOXIC SALTS USED AS ANTITUMOR AGENT | GUTTAG ALVIN (US) | 2002-08-20 | — | — | US | disclosed |
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | GUTTAG ALVIN (US) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038480-A1 | COMPOUNDS THAT MODULATE AUTOIMMUNITY AND METHODS OF USING THE SAME | HLA-DRB1, IAPP, CD74 | TDP1 4665/4885PKM 3485/4885PTGDR2 1496/4885 |
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | PTGES3, HPGDS, PTGES | TDP1 665/4885PKM 4303/4885PTGDR2 45/4885 |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GALE, TPT1, HPSE | TDP1 1530/4885PKM 4602/4885PTGDR2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.